Topical skin composition

Abstract

The present invention relates to a topical skin composition comprising, as an active ingredient, a composite ingredient containing an ergothioneine and an Akebia quinata extract.

Description

Composition for external skin application

[0001] Cross-citation with related applications

[0002] This application claims the benefit of priority from Korean Patent Application No. 10-2024-0031106, filed March 5, 2024, the entire contents of which are incorporated herein by reference.

[0003] Technology field

[0004] The present invention relates to a composition for external application to the skin.

[0005]

[0006] Skin aging is a natural change that occurs with age, but it is also caused by many exogenous factors such as ultraviolet rays, smoking, dietary habits, and environmental pollution.

[0007] Skin aging can manifest as a decline in appearance, loss of skin texture, increased wrinkles, dullness, and decreased skin function. As skin ages, its color tone changes, becoming less red, more yellow, and less luminous, resulting in a dull appearance.

[0008] Factors that cause dullness include skin pigmentation, protein glycation, and oxidation.

[0009] Currently, aminoguanidine is the most promising glycation inhibitor drug that inhibits the formation of advanced glycation end products by binding to Amadori products with nucleophilic hydrazine and preventing cross-linking with proteins. However, there are concerns about side effects related to catalase inhibition when administered for a long period of time, and efforts have been made to search for new, safe and effective protein glycation inhibitors.

[0010] Furthermore, reactive oxygen species generated in the body denature biological proteins, and these denatured proteins become more reactive with sugars, inducing glycation. Based on this mechanism, there is an urgent need to develop natural anti-glycation substances that can suppress reactive oxygen species-induced oxidative stress and inhibit glycation reactions with proteins.

[0011] <Prior Art Literature>

[0012] Korean Patent Publication No. 10-2017-0137544

[0013]

[0014] The present invention provides a composition for external skin application that is safe and has few side effects on the human body, while having excellent skin anti-glycation, skin antioxidant, skin tone improvement, skin whitening, skin elasticity improvement, skin wrinkle improvement, and skin barrier strengthening effects.

[0015]

[0016] According to one embodiment, a composition for external application to the skin is provided, which contains a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient.

[0017] The above complex component may be included in an amount of 0.001 wt% to 10 wt% based on the total weight of the above skin external preparation composition.

[0018] The above ergothioneine and Akebia quinata extract may be included in a weight ratio of 1:10 to 10:1.

[0019] The above extract of the vine can be extracted using at least one selected from the group consisting of water and organic solvents.

[0020] The above organic solvent may be a C1 to C10 alcohol.

[0021] The above extract of the vine can be obtained by a cold extraction method.

[0022] The above skin external preparation composition can suppress skin browning caused by glycoaldehyde, a glycation inducer.

[0023] The above skin external preparation composition can suppress skin solidification caused by methylglyoxal, a glycation inducer.

[0024] The above skin external preparation composition can exhibit DPPH radical scavenging activity.

[0025] The above skin external preparation composition can exhibit skin keratinocyte proliferation activity.

[0026] The above skin external composition can be used for skin anti-glycation, skin antioxidant, skin tone improvement, skin whitening, skin elasticity improvement, skin wrinkle improvement, and skin barrier strengthening.

[0027]

[0028] The external skin composition according to the present invention contains ergothioneine and an extract of yarrow as active ingredients, so that it is safe and has few side effects on the human body, while exhibiting excellent effects in anti-glycation of the skin, anti-oxidation of the skin, improvement of skin tone, whitening of the skin, improvement of skin elasticity, improvement of skin wrinkles, and strengthening of the skin barrier.

[0029]

[0030] Below, implementation examples are described in detail so that those skilled in the art can easily implement them. However, the implementation examples can be implemented in various different forms and are not limited to the implementation examples described herein.

[0031] The terminology used herein is for the purpose of describing embodiments only and is not intended to limit the present invention. In this specification, the singular also includes the plural unless specifically stated otherwise. As used herein, the terms "comprises" and / or "comprising" do not exclude the presence or addition of one or more other components in addition to the mentioned components. Like reference numerals refer to like components throughout the specification, and "and / or" includes each and any combination of one or more of the mentioned components. Although "first", "second", etc. are used to describe various components, these components are not limited by these terms. These terms are only used to distinguish one component from another. Therefore, it should be understood that a first component mentioned below may also be a second component within the technical spirit of the present invention.

[0032] Unless otherwise defined, all terms (including technical and scientific terms) used herein may be used in their common sense to those skilled in the art to which the present invention pertains. Furthermore, terms defined in commonly used dictionaries are not to be interpreted ideally or excessively unless explicitly and specifically defined otherwise.

[0033] In the present invention, “skin” is a concept that includes not only the face but also the scalp and the entire body.

[0034] In the present invention, “containing as an active ingredient” means including a complex ingredient including ergothioneine and Akebia quinata extract in an amount capable of exhibiting a skin improvement effect.

[0035]

[0036] A composition for external application to the skin according to one embodiment contains a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient.

[0037] In one embodiment, the ergothioneine is an amino acid compound present in various plants and animals, which has unique physiological functions such as antioxidant, free radical scavenging, metal ion chelating, protection against ultraviolet damage, and cancer inhibition, and in some aspects is superior to natural antioxidants such as glutathione.

[0038] In one embodiment, the above-mentioned creeper is a deciduous vine belonging to the creeper family, and grows wild throughout the country. Male and female flowers bloom separately in different shapes on a single tree and are used for ornamental purposes. In addition, the young leaves and fruit are edible, and the roots and branches are used medicinally. Specifically, the young shoots and young stems were eaten as vegetables, and the flowers were dried and used as a substitute for perfume. The boiled stem water was used as a yellow or yellowish-brown dye, and it was also used medicinally as it is particularly effective as an anti-inflammatory diuretic, treating urinary tract infections, urethritis, sore throats, and as a psychotropic tranquilizer. The roots and bark are effective for urinary disorders, and the fruit is effective as a diuretic, stroke, and arthritis.

[0039] The above extract of the vine can be made of at least one selected from the group consisting of the peel, pulp, fruit, leaf, stem, branch and root of the vine, preferably the whole plant having a high proportion of vine fruits.

[0040] The above extract of the quince tree can be obtained using an extraction method and extraction solvent known in the art, and preferably can be extracted using at least one selected from the group consisting of water and organic solvents. The extracted extract of the quince tree can be used directly or after being concentrated and / or dried.

[0041] The organic solvent may be a C1 to C10 alcohol, a C1 to C6 alcohol, or a lower alcohol such as methanol, ethanol, propanol, and butanol of C1 to C4.

[0042] The extraction method of the above-mentioned vine is not particularly limited, and examples thereof include cold extraction, ultrasonic extraction, reflux extraction, hot water extraction, etc., and a cold extraction method can be used as a specific example.

[0043] In the case of the above cold extraction, the above-mentioned vine and an alcohol solution are mixed and cold extracted at a temperature of 15°C to 25°C for 36 to 60 hours or 36 to 48 hours. Under the conditions described above, the effective ingredients can be extracted with high efficiency while minimizing the loss of the effective ingredients due to the cold extraction temperature.

[0044] The above cold-extracted extract of the quince plant may be subjected to a filtration step. In the filtration step, a filter paper having pore sizes of 2 μm to 10 μm or 6 μm to 10 μm may be used. Under the conditions described above, the filtrate of the quince plant extract can be effectively collected during filtration, and the residue remaining during the filtration process can be subjected to another extraction process, and this process may be repeated multiple times.

[0045] The extract that has undergone the above filtration step can be produced in the form of a dry powder by concentrating under reduced pressure at a temperature of 45°C or lower, or between 20°C and 45°C. The extract can be prevented from boiling over during the concentration under reduced pressure under the conditions described above.

[0046] In one embodiment, the complex component may be included in an amount of 0.001 wt% to 10 wt%, 0.01 wt% to 5 wt%, or 0.1 wt% to 3 wt% based on the total weight of the external skin composition. An external skin composition containing the complex component as an active ingredient in an amount within the above-described range may have excellent effects in anti-glycation of the skin, anti-oxidation of the skin, improvement of skin tone, whitening of the skin, improvement of skin elasticity, improvement of skin wrinkles, and strengthening of the skin barrier.

[0047] In one embodiment, the ergothioneine and Akebia quinata extract may be included in a weight ratio of 1:10 to 10:1, 1:8 to 8:1, or 1:4 to 4:1, preferably 1:2 to 2:1. A skin external preparation composition containing a complex component of ergothioneine and Akebia quinata extract as an active ingredient in a weight ratio within the above-mentioned range may have superior effects in skin anti-glycation, skin antioxidant, skin tone improvement, skin whitening, skin elasticity improvement, skin wrinkle improvement, and skin barrier strengthening.

[0048] The above-mentioned external skin composition can suppress skin browning caused by glycoaldehyde, a glycation inducer. Glycoaldehyde, one of the glycation inducer components, induces glycation and causes skin discoloration, i.e., browning. In this regard, when the composite component according to the present invention is contained as an active ingredient, it can suppress skin browning caused by glycoaldehyde, thereby achieving skin whitening and skin tone improvement effects.

[0049] The above-mentioned external skin composition can inhibit skin hardening caused by methylglyoxal, a glycation inducer. Methylglyoxal, a glycation inducer, induces glycation and promotes skin hardening. In this regard, when the composite component according to the present invention is included as an active ingredient, it can have the effects of improving skin elasticity and reducing wrinkles by inhibiting skin hardening.

[0050] The above-mentioned external skin composition can exhibit DPPH radical scavenging activity. Specifically, the external skin composition containing the complex component according to the present invention as an active ingredient can be confirmed through antioxidant activity measurement using the DPPH (1,1-diphenyl-2-picrydrazyl) method, and can have an excellent antioxidant effect through DPPH radical scavenging activity.

[0051] The above-mentioned external skin composition can exhibit skin keratinocyte proliferation activity. Specifically, the external skin composition containing the complex component according to the present invention as an active ingredient can have a skin barrier improvement effect through excellent cell proliferation activity.

[0052]

[0053] In one embodiment, the external skin composition may be a cosmetic composition. The cosmetic composition may include a carrier acceptable for cosmetic formulations. Here, the term "acceptable carrier for cosmetic formulations" refers to a compound or composition already known and used, or a compound or composition to be developed in the future, that can be included in cosmetic formulations and that does not exhibit toxicity, instability, or irritation beyond what the human body can tolerate when in contact with the skin.

[0054] The carrier may be included in an amount of 1 wt% to about 99.99 wt%, or 90 wt% to about 99.99 wt%, based on the total weight of the cosmetic composition of the present invention. However, since the above ratio varies depending on the formulation of the cosmetic composition of the present invention, which will be described later, and on the specific application site (face, neck, etc.) or the desired application amount thereof, the above ratio should not be understood as limiting the scope of the present invention in any way.

[0055] Examples of the above carriers include alcohol, oil, surfactant, fatty acid, silicone oil, humectant, moisturizer, viscosity modifier, emulsion, stabilizer, ultraviolet scattering agent, ultraviolet absorber, colorant, fragrance, etc. Compounds / compositions that can be used as the above alcohol, oil, surfactant, fatty acid, silicone oil, humectant, moisturizer, viscosity modifier, emulsion, stabilizer, ultraviolet scattering agent, ultraviolet absorber, colorant, fragrance, etc. are already known in the art, so a person skilled in the art can select and use an appropriate corresponding substance / composition.

[0056] The above skin external preparation composition may contain, in addition to the above effective ingredients, glycerin, butylene glycol, propylene glycol, polyoxyethylene hydrogenated castor oil, ethanol, triethanolamine, etc., and may contain trace amounts of preservatives, fragrances, coloring agents, purified water, etc., as needed.

[0057] In addition, the above-mentioned skin external preparation composition may further include a conventionally well-known physiologically active ingredient or other placental cell culture or extract.

[0058] The above skin is a concept that includes not only the face but also the scalp and the entire body, and as a skin external composition that can be applied to the scalp, there are shampoos, rinses, treatments, hair tonics, etc., and as a body cleanser that can be applied to the entire body, it can be manufactured in various forms.

[0059] The method for manufacturing the above-described skin external preparation composition is not limited to the above-described manufacturing method, and a person having ordinary knowledge in the technical field to which the present invention pertains can also manufacture the composition using a method that partially modifies the above-described manufacturing method.

[0060] The above-mentioned external skin composition may further contain adjuvants commonly used in the field of cosmetics or dermatology, such as fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, humectants, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles, or any other ingredients commonly used in cosmetics. In addition, the above-mentioned ingredients may be introduced in amounts commonly used in the field of dermatology.

[0061] The above skin external preparation composition may be a pharmaceutical composition.

[0062] The above pharmaceutical composition can be used for the prevention or treatment of inflammatory skin diseases.

[0063] The above inflammatory skin disease may be at least one selected from the group consisting of dermatitis, allergic dermatitis, irritant dermatitis, seborrheic dermatitis, atopic dermatitis, sensitive skin disease, pruritus, eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, rash, and acne.

[0064] The pharmaceutical composition may contain conventional fillers, bulking agents, binders, disintegrants, anticoagulants, lubricants, wetting agents, pH regulators, nutrients, vitamins, electrolytes, alginic acid and its salts, pectic acid and its salts, protective colloids, glycerin, flavorings, emulsifiers, or preservatives.

[0065] The pharmaceutical composition may comprise a pharmaceutically acceptable carrier, examples of which include at least one selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin, and saline solution.

[0066] The formulation of the above pharmaceutical composition may vary depending on the method of use, and may be formulated using methods well known in the art to which the present invention pertains so as to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.

[0067]

[0068] The present invention provides a use for a complex composition for external application to the skin comprising ergothioneine and an extract of Akebia quinata.

[0069] The present invention provides a use for an external skin preparation composition containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient for inhibiting skin browning.

[0070] The present invention provides a use for a composition for external application for skin containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient for inhibiting skin solidification.

[0071] The present invention provides a use for DPPH radical scavenging of a composition for external application to the skin containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient.

[0072] The present invention provides a use for a composition for external application for skin containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient for the proliferation of skin keratinocytes.

[0073] The present invention provides a composition for external application for skin containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient for use in anti-glycation of skin, anti-oxidation of skin, improvement of skin tone, whitening of skin, improvement of skin elasticity, improvement of skin wrinkles, and strengthening of skin barrier.

[0074] The present invention provides a composition for external application of skin containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient for use in the prevention or treatment of inflammatory skin diseases.

[0075] The above inflammatory skin disease may be at least one selected from the group consisting of dermatitis, allergic dermatitis, irritant dermatitis, seborrheic dermatitis, atopic dermatitis, sensitive skin disease, pruritus, eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, rash, and acne.

[0076] The compound composition containing the above ergothioneine and Akebia quinata extract is as described above.

[0077]

[0078] The present invention provides a method for inhibiting skin browning by applying to the skin of an animal a composition for external application containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient.

[0079] The present invention provides a method for inhibiting skin solidification by applying a composition for external application to the skin of an animal, the composition containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient.

[0080] The present invention provides a method for scavenging DPPH radicals by applying a composition for external application for skin containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient to the skin of an animal.

[0081] The present invention provides a method for proliferating skin keratinocytes by applying a composition for external application to the skin of an animal, the composition containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient.

[0082] The present invention provides a method for improving skin anti-glycation, skin antioxidant, skin tone, skin whitening, skin elasticity, skin wrinkles, and skin barrier strengthening by applying a composition for external application containing a complex ingredient including ergothioneine and Akebia quinata extract as an active ingredient to the skin of an animal.

[0083] The compound composition containing the above ergothioneine and Akebia quinata extract is as described above.

[0084] The above animal may be a human.

[0085]

[0086] The present invention provides a composition for external application to the skin containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient for use as a cosmetic composition.

[0087] The present invention provides a use of a composition for external application to the skin containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient as a pharmaceutical composition.

[0088] The present invention provides a use of a pharmaceutical composition containing a complex composition comprising ergothioneine and an extract of Akebia quinata as an active ingredient for the prevention or treatment of inflammatory skin diseases.

[0089] The above inflammatory skin disease may be at least one selected from the group consisting of dermatitis, allergic dermatitis, irritant dermatitis, seborrheic dermatitis, atopic dermatitis, sensitive skin disease, pruritus, eczematous skin disease, dry eczema, erythema, urticaria, psoriasis, rash, and acne.

[0090] The compound composition containing the above ergothioneine and Akebia quinata extract is as described above.

[0091]

[0092] The present invention provides a method for producing a composition for external application to the skin containing a complex component including ergothioneine and an extract of Akebia quinata as an active ingredient.

[0093] The compound composition containing the above ergothioneine and Akebia quinata extract is as described above.

[0094]

[0095] Below, specific embodiments of the present invention are presented. However, the following examples are intended solely to illustrate or explain the present invention and should not be construed as limiting it. Furthermore, any details not described herein are technically feasible to those skilled in the art, and therefore, their description is omitted.

[0096]

[0097] [Manufacturing Example]: Manufacturing of Aster vine extract

[0098] 100 g of the whole plant of the plant (source: Cheongju) was collected, added to 1 L of 70% ethanol solution, and steeped at a temperature of 15 to 25 °C for 48 hours, then filtered through Whatman No. 2. The filtered extract was concentrated under reduced pressure at 45 °C or lower to produce dried powder of the plant.

[0099]

[0100] [Examples and Comparative Examples]

[0101] The composite components of Examples 1 to 7, each consisting of two components, were prepared by mixing the extract of the vine prepared in the manufacturing example and ergothioneine (EGT) represented by the following chemical formula 1 in the weight ratio shown in Table 1 below. For comparative experiments, single component samples were prepared in Comparative Examples 1 and 2, respectively.

[0102] [Chemical Formula 1]

[0103]

[0104] CAS number: 497-30-3

[0105] Where to buy: Sigma-aldrich (USA)

[0106]

[0107] Sample Example 1 EGT: Mugwort extract = 1:1 Example 2 EGT: Mugwort extract = 1:2 Example 3 EGT: Mugwort extract = 2:1 Example 4 EGT: Mugwort extract = 1:4 Example 5 EGT: Mugwort extract = 4:1 Example 6 EGT: Mugwort extract = 1:8 Example 7 EGT: Mugwort extract = 8:1 Comparative Example 1 EGT Comparative Example 2 Mugwort extract

[0108]

[0109] [Experimental Example]

[0110] Experimental Example 1: Inhibition of browning by anti-glycation activity

[0111] To determine the degree of browning due to saccharification reaction, 20 mg / ml of bovine serum albumin (BSA; Sigma, St Louis, USA) and 20 mg / ml of glycolaldehyde (GAD; Sigma, St Louis, USA) were dissolved in PBS buffer (pH 7.4) as saccharification reaction substrates, and then the samples of Examples 1 to 7 and Comparative Examples 1 and 2 were diluted to an appropriate concentration, mixed, and saccharification reaction was performed at 37°C for 24 hours.

[0112] The color difference ΔE value of the reaction solution was measured using a colorimeter 24 hours after the saccharification reaction, and the browning rate was calculated using the following mathematical formula 1, and the degree of browning is shown in Table 2.

[0113] [Mathematical Formula 1]

[0114] Browning rate (%) = (B / A) x 100

[0115] (In the above mathematical formula 1,

[0116] A is the color difference ΔE value of the control group that did not process the sample,

[0117] B is the color difference ΔE value of the experimental group treated with each sample of Examples 1 to 7 and Comparative Examples 1 and 2.)

[0118] Sample (500 ppm) ΔE value change rate (%) 24H Example 1 EGT: Mugwort extract = 1:163.45 70.97 Example 2 EGT: Mugwort extract = 1:265.5 37 3.29 Example 3 EGT: Mugwort extract = 2:160.2 36 7.36 Example 4 EGT: Mugwort extract = 1:468.5 37 6.65 Example 5 EGT: Mugwort extract = 4:166.5 17 4.39 Example 6 EGT: Mugwort extract = 1:872.98 1.53 Example 7 EGT: Mugwort extract = 8:168.76 76.90 Comparative Example 1 EGT 70.5 37 8.88 Comparative Example 2. Extract of the vine 78.4687.75. Control group: BSA+GAD 89.41100. Positive control group: Metformin 1% 70.4478.78

[0119] As shown in Table 2 above, it can be seen that browning of the reaction solution is clearly induced during the saccharification reaction with BSA and GAD, and when the samples of Examples 1 to 7 according to one embodiment are used, especially when the samples of Examples 1 to 5 are used, the browning inhibition effect due to anti-glycation is superior compared to when the samples of Comparative Examples 1 and 2 are used, thereby showing skin whitening and skin tone improvement effects.

[0120]

[0121] Experimental Example 2: Inhibitory activity of solidification by antiglycation

[0122] In order to confirm the degree of solidification by saccharification reaction, 20 mg / ml of bovine serum albumin (BSA; Sigma, St Louis, USA) and 50 mg / ml of methylglyoxal (MGO; Sigma, St Louis, USA) were dissolved in PBS buffer (pH 7.4) as saccharification reaction substrates, and then the samples of Examples 1 to 7 and Comparative Examples 1 and 2 were diluted to an appropriate concentration and mixed, and saccharification reaction was performed for 9 hours in a Turbiscan (Formulaction, France) device set at 37℃. Since the Turbiscan device can measure the transmittance of a light source over time, it can be confirmed that the turbidity increases as solidification progresses by saccharification reaction. The TSI (Turbiscan Stability Index), which is a stability index value measured by the device, was calculated according to Equation 2, and then the solidification rate was calculated using Equation 3, and the degree of solidification is shown in Table 3.

[0123] [Equation 2]

[0124]

[0125] [Equation 3]

[0126] Solidification rate (%) = (B / A) x 100

[0127] (In the above mathematical formula 3,

[0128] A is the TSI value of the control group that did not process the sample,

[0129] B is the TSI value of the experimental group treated with the samples of Examples 1 to 7 and Comparative Examples 1 and 2.)

[0130] Sample (500 ppm) TSI value Solidification rate (%) Example 1 EGT: Arugula vine extract = 1:112.82 7.83 Example 2 EGT: Arugula vine extract = 1:2 11.12 4.13 Example 3 EGT: Arugula vine extract = 2:113.72 9.78 Example 4 EGT: Arugula vine extract = 1:4 10.12 1.96 Example 5 EGT: Arugula vine extract = 4:113.42 9.13 Example 6 EGT: Arugula vine extract = 1:8 10.32 2.39 Example 7 EGT: Arugula vine extract = 8:116.33 5.43 Comparative Example 1 EGT 18.23 9.57 Comparative Example 2 Arugula Extract 1532.61 Control group BSA+MGO 46100.00 Positive control group Metformin 1% 2.24.78

[0131] Through the above Table 3, it can be seen that the solidification of the reaction solution is clearly induced during the saccharification reaction with BSA and MGO, and when the samples of Examples 1 to 7 according to one embodiment are used, especially when the samples of Examples 1 to 5 are used, it can be seen that the effects of improving skin elasticity and improving wrinkles are shown through the suppression of solidification by excellent anti-glycation compared to when the samples of Comparative Examples 1 and 2 are used.

[0132]

[0133] Experimental Example 3: Antioxidant Activity

[0134] Antioxidant activity was measured by the DPPH (1,1-diphenyl-2-picrydrazyl) method. The DPPH method measures free radical scavenging activity by reducing power using a free radical called DPPH. Fifty microliters of each sample was added to a 96-well plate using the serial dilution method, and 100 microliters of a 0.4 mM DPPH (Sigma, St. Louis, USA) solution was added and reacted for 15 minutes. The degree of absorbance decrease due to DPPH reduction by the sample was compared with the absorbance of the control group, and the free radical scavenging rate was measured at a wavelength of 517 nm. The results are shown in Table 4.

[0135] Free radical scavenging activity (%) was calculated using the following mathematical formula 4.

[0136] [Equation 4]

[0137] Free radical scavenging activity (%) = (A - B) / A x 100

[0138] (In the above mathematical formula 4,

[0139] A is the absorbance of the control group that did not process the sample,

[0140] B is the absorbance of the experimental group treated with the samples of Examples 1 to 7 and Comparative Examples 1 and 2.)

[0141] Sample (100 ppm)DPPH radical scavenging rate (%)Example 1EGT: Arugula vine extract = 1:186.04Example 2EGT: Arugula vine extract = 1:275.97Example 3EGT: Arugula vine extract = 2:195.83Example 4EGT: Arugula vine extract = 1:435.55Example 5EGT: Arugula vine extract = 4:196.83Example 6EGT: Arugula vine extract = 1:810.45Example 7EGT: Arugula vine extract = 8:175.97Comparative Example 1EGT73.52Comparative Example 2Arugula vine extract7.65

[0142] Through the above Table 4, EGT and the extract of the vine were confirmed to have DPPH radical scavenging activity, and it can be seen that when the samples of Examples 1 to 7 according to one embodiment were used, especially when the samples of Examples 1 to 5 were used, an excellent antioxidant effect through DPPH radical scavenging activity was shown compared to when the samples of Comparative Examples 1 and 2 were used.

[0143]

[0144] Experimental Example 4: Skin keratinocyte proliferation activity

[0145] To measure the proliferation activity of skin keratinocytes, cells were seeded at 1x10 4After dispensing into a 96-well plate at a concentration of 10 cells / well, the cells were cultured at 37°C and 5% CO2 for 24 hours. After removing the culture medium, the samples of Examples 1 to 7 and Comparative Examples 1 and 2 were treated to the cells at appropriate concentrations in serum-free medium and further cultured for 24 hours. In order to check the cell viability after culture, the culture medium was removed, and 200 μl of an MTT solution at a concentration of 0.5 mg / ml was treated per well and reacted for 3 hours. The produced formazan was dissolved in 100 μl of DMSO and the absorbance was measured at a wavelength of 540 nm using a micro-plate reader. As a normal control, the cell viability of the well not treated with the extract was set to 100%. The cell viability of the sample treatment groups of Examples 1 to 7 and Comparative Examples 1 and 2 was calculated according to Equation 5, and the results are shown in Table 5.

[0146] [Equation 5]

[0147] Skin keratinocyte viability (%) = (A / B) x 100

[0148] A: Absorbance of the test group treated with the sample

[0149] B: Absorbance of the untreated control sample

[0150] Sample (50 ppm) Cell viability (%) Example 1 EGT: Arugula vine extract = 1:1110.16 Example 2 EGT: Arugula vine extract = 1:2112.84 Example 3 EGT: Arugula vine extract = 2:1116.54 Example 4 EGT: Arugula vine extract = 1:4105.21 Example 5 EGT: Arugula vine extract = 4:1108.69 Example 6 EGT: Arugula vine extract = 1:8100.05 Example 7 EGT: Arugula vine extract = 8:1100.4 Comparative Example 1 EGT 94.87 Comparative Example 2 Arugula vine extract 91.54

[0151] Through the above Table 5, it was confirmed that when EGT and 50 ppm of the extract of the vine (Comparative Examples 1 and 2) were treated to skin keratinocytes for 24 hours, a cell viability rate of over 90% was achieved. In addition, it can be seen that when the samples of Examples 1 to 7 according to one embodiment were used, particularly when the samples of Examples 1 to 5 were used, the skin barrier improvement effect through superior cell proliferation activity was shown compared to when the samples of Comparative Examples 1 and 2 were used.

[0152]

[0153] Experimental Example 5: Skin Safety Test

[0154] In order to confirm the skin safety of the external skin preparation composition according to one embodiment, a patch test was conducted on 30 adult men and women, in which 20,000 ppm of the samples of Examples 1 to 7 and Comparative Examples 1 and 2 were applied, to evaluate skin safety. The first reading was performed 1 hour after the patch was removed, and the second reading was performed 24 hours after the patch was removed. In order to determine the intensity of skin irritation, a weight was given according to the degree of positive skin reaction to obtain an average skin reaction score, and the skin irritation of the extract sample was visually assessed, and the results are shown in Table 6 below.

[0155] After 1 hour of the sample After 24 hours Average skin reaction score Judgment Skin positive reaction degree Weighting 0.51230.5123 Example 120,000 ppm Number of people (persons) 0000000000 Non-irritating Example 220,000 ppm Number of people (persons) 000000000 Non-irritating Example 320,000 ppm Number of people (persons) 000000000 Non-irritating Example 420,000 ppm Number of people (persons) 000000000 Non-irritating Example 520,000 ppm Number of people (persons) 000000000 Non-irritating Example 620,000 ppm Number of people (persons) 000000000 Non-irritating Example 720,000 ppm Number of people (persons) 000000000 Non-irritating Comparison Example 120,000 ppm Number of people (persons) 000000000 Non-irritating Comparison Example 220,000 ppm Number of people (persons) 000000000 Non-irritating

[0156] As shown in Table 6 above, no one showed a positive skin reaction with a weight of 0.5 to 3 in the first and second readings after removing the patch to which 20,000 ppm of the samples of Examples 1 to 7 were applied, and thus it can be confirmed that there was no skin irritation when the samples of Examples 1 to 7 at 20,000 ppm or less were applied to the skin. In other words, it can be seen that the external skin composition containing the samples of Examples 1 to 7 according to one embodiment did not cause skin irritation.

[0157]

[0158] Hereinafter, based on the results of the above experimental examples, various formulation examples using the samples of Examples 1 to 7 are presented. However, these formulation examples are intended to illustrate one embodiment, and it is obvious to those skilled in the art that the formulation of one embodiment is not limited to these formulation examples.

[0159]

[0160] [Formulation example]

[0161] Formulation Example 1: Toner

[0162] Ingredients (weight %) Formulation Example 1: Toner 1-11-21-31-41-51-61-7 Example 11.0------- Example 2-1.0----- Example 3--1.0----- Example 4---1.0----- Example 5----1.0--- Example 6-----1.0- Example 7------1.0 Trehalose 2222222 Glycerin 55555551,2-Hexanediol 2222222 EDTA-2Na 0.020.020.020.020.020.020.02 Purified water Residual amount Residual amount Residual amount Residual amount Residual amount

[0163]

[0164] Formulation Example 2: Essence

[0165] Ingredients (weight %) Formulation Example 2: Essence 1-11-21-31-41-51-61-7 Example 11.0------Example 2-1.0-----Example 3--1.0----Example 4---1.0---Example 5----1.0--Example 6-----1.0-Example 7-------1.0 Trehalose 2222222 Glycerin 101010101010101,2-Hexanediol 2222222 Carbomer 0.150.150.150.150.150.150.15 Tromethamine 0.10.10.10.10.10.10.1 EDTA-2Na 0.020.020.020.020.020.020.02 Purified water Residual amount Residual amount Residual amount Residual amount Residual amount

[0166]

[0167] Formulation Example 3: Cream

[0168] Ingredients (% by weight) Formulation Example 3: Cream 1-11-21-31-41-51-61-7 Example 11.0------- Example 2-1.0----- Example 3--1.0----- Example 4---1.0--- Example 5----1.0--- Example 6-----1.0- Example 7------1.0 Sunflower Seed Oil 3333333 Ethylhexyl Palmitate 7777777 PEG-100 Stearate, Glyceryl Stearate 2222222 Polysorbate 60 1111111 Sorbitan Stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Trehalose 2222222 Glycerin 10 10 10 10 10 10 1,2-Hexanediol 222222 Carbomer 0.3 0.3 0.3 0.3 0.3 0.3 0.3 Tromethamine 0.2 0.2 0.2 0.2 0.2 0.2 0.2 EDTA-2Na 0.0 20 ...

Claims

1. A composition for external application to the skin containing a complex ingredient including ergothioneine and Akebia quinata extract as an active ingredient.

2. In paragraph 1, A composition for external use of the skin, wherein the above complex component is included in an amount of 0.001 wt% to 10 wt% based on the total weight of the composition for external use of the skin.

3. In paragraph 1, A composition for external application to the skin, wherein the above ergothioneine and Akebia quinata extract are included in a weight ratio of 1:10 to 10:

1.

4. In paragraph 1, A composition for external application to the skin, wherein the above extract of the vine is extracted using at least one selected from the group consisting of water and organic solvents.

5. In paragraph 4, A composition for external application of skin, wherein the organic solvent is a C1 to C10 alcohol.

6. In paragraph 1, A composition for external use in the skin, wherein the above extract of the vine is obtained by a cold extraction method.

7. In paragraph 1, The above skin external preparation composition is a skin external preparation composition that suppresses skin browning caused by glycoaldehyde, a glycation inducer.

8. In paragraph 1, The above skin external preparation composition is a skin external preparation composition that suppresses skin solidification caused by methylglyoxal, a glycation inducer.

9. In paragraph 8, The above skin external preparation composition is a skin external preparation composition that exhibits DPPH radical scavenging activity.

10. In paragraph 1, The above skin external preparation composition is a skin external preparation composition that exhibits skin keratinocyte proliferation activity.

11. In paragraph 1, The above skin external preparation composition is a skin external preparation composition for skin anti-glycation, skin antioxidant, skin tone improvement, skin whitening, skin elasticity improvement, skin wrinkle improvement, and skin barrier strengthening.